PRGS&Tech

Name

PRGS&Tech

Website

https://prgst.com

Company type

Private

Founded year

2017

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Busan

HQ country

South Korea

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Core offering

PRGS&Tech is a research and development center that develops treatments for rare diseases. The company is engaged in therapeutic R&D activities to address unmet medical needs in the rare disease space, operating as a privately held entity based in Busan, South Korea.

Differentiator

Problem solved

Functional benefit

Products and services

• Rare disease therapeutics R&D Research and development services focused on discovering and developing therapeutic treatments for rare diseases, targeted at pharmaceutical/biotech partners for licensing or co-development.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Direct peers

• BridgeBio Pharma: US-based rare disease-focused drug developer with a multi-asset pipeline; directly comparable strategic model (small focused teams pursuing rare disease therapeutics), though at much larger scale.
• AbCellera Biologics: Biotechnology company developing antibody therapeutics, including for rare diseases, with a focused R&D-centric operating model comparable to PRGS&Tech's lean structure.
• LegoChem Biosciences: Korean clinical-stage biotech developing therapeutics including in rare and serious disease indications, with comparable company size and Korean R&D base to PRGS&Tech.
• Ultragenyx Pharmaceutical: Pure-play rare disease biotechnology company developing and commercializing therapeutics for rare and ultra-rare genetic diseases; directly comparable therapeutic focus.

Broad incumbents

• Hanmi Pharmaceutical: Established Korean pharmaceutical company with rare disease and specialty pipeline programs; provides a comparable larger incumbent view on the Korean rare disease drug development landscape.
• Yuhan Corporation: Korean pharmaceutical company with rare disease and specialty therapeutics programs; a relevant Korean incumbent comparable in therapeutic orientation.
• SK Biopharmaceuticals: Korea-based biopharmaceutical company operating in CNS and rare/specialty disease drug development; substantially larger and more advanced, but operating in the same Korean biotech ecosystem and rare-disease orientation.
• BioMarin Pharmaceutical: Global biotechnology company dedicated to rare disease therapeutics across multiple indications; comparable strategic positioning around rare disease specialty markets.

Emerging players

• CRISPR Therapeutics: Clinical-stage gene editing company with rare disease programs (e.g., hemoglobinopathies); overlapping modality and rare-disease focus, though at significantly more advanced and well-capitalized stage.
• Taysha Gene Therapies: Clinical-stage gene therapy company focused exclusively on rare monogenic CNS diseases; similar early-to-mid stage profile targeting rare disease indications.

Market position

Customer concentration

• Facebookfacebook.com/100080985699452
• LinkedInlinkedin.com/company/prgst

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PRGS&Tech